Rain Therapeutics Inc

RAIN | $1.21 0.0% 3.7M

(0.0% 1d) (0.0% 1m) (-83.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (979.26% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 33,371,736
https://www.rainthera.com
Sec Filling | Patents | n/a employees

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

cancer t-cell genetic ceiling

add to watch list Paper trade email alert is off

High Tide Inc.

HITI | $2.18 -2.68% 260K

Manufacturing

(0.0% 1d) (37.8% 1m) (74.3% 1y) (0.0% 2d) (0.0% 3d) (-8.5% 7d) (NaN% volume)
Earnings Calendar: 2024-01-29
Market Cap: $ 172,951,318
https://hightideinc.com
Sec Filling | Patents | n/a employees

(CA) High Tide is a retail-focused cannabis company enhanced by the manufacturing and distribution of consumption accessories. The Company is the largest Canadian retailer of recreational cannabis as measured by revenue, with 80 branded retail cannabis locations spanning Ontario, Alberta, Manitoba and Saskatchewan. High Tide's retail segment features the Canna Cabana,KushBar, Meta Cannabis Co., Meta Cannabis Supply Co. and NewLeaf Cannabis banners, with additional locations under development across the country. High Tide has been serving consumers for over a decade through its numerous consumption accessory businesses including e-commerce platforms Grasscity.com and CBDcity.com, and its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide's strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value.

msa brands

add to watch list Paper trade email alert is off

LifeMD Inc

LFMD | $9.79 1.87% 110K

Manufacturing

(0.0% 1d) (-11.3% 1m) (478.9% 1y) (0.0% 2d) (0.0% 3d) (-2.5% 7d) (-41.22% volume)
Earnings Calendar:
Market Cap: $ 395,183,600
https://lifemd.com
Sec Filling | Patents | 56 employees

LifeMD, Inc. (formerly Conversion Labs) is a leading telehealth company that is transforming the healthcare landscape with direct-to-patient product and service offerings. LifeMD's telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home.

treatment

add to watch list Paper trade email alert is off

NRX Pharmaceuticals Inc

NRXP | $4.38 -10.61% 140K

Manufacturing

(0.0% 1d) (851.5% 1m) (665.9% 1y) (0.0% 2d) (0.0% 3d) (-11.4% 7d) (-81.66% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 419,165,036
https://www.bigrockpartners.com/spac/spac_aboutus.html
Sec Filling | Patents | 2 employees

(US) Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Big Rock Partners' management team includes Richard Ackerman, Chairman, President, and Chief Executive Officer, and Bennett Kim, Chief Financial Officer, Chief Investment Officer, Corporate Secretary and Director.

covid treatment vaccine acquisitions zyesami aviptadil blank check

add to watch list Paper trade email alert is off

Nuwellis Inc

NUWE | $0.336 -8.75% 90K

Manufacturing

(0.0% 1d) (-15.8% 1m) (-92.0% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (16.79% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,285,285
https://www.nuwellis.com
Sec Filling | Patents | 15027 employees

(US) Nuwellis, Inc. , formally CHF Solutions, is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions

brands

add to watch list Paper trade email alert is off

Palisade Bio Inc

PALI | $6.5 56.25% 22M

Manufacturing

(0.0% 1d) (1047.0% 1m) (115.5% 1y) (0.0% 2d) (0.0% 3d) (2.2% 7d) (NaN% volume)
Earnings Calendar: 2022-11-11
Market Cap: $ 83,011,598
https://www.palisadebio.com
Sec Filling | Patents | n/a employees

(US) Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

education msa gastrointestinal

add to watch list Paper trade email alert is off

Cryo-Cell International, Inc.

CCEL | $6.79 -4.1% 6.6K

Manufacturing

(0.0% 1d) (22.3% 1m) (99.5% 1y) (0.0% 2d) (0.0% 3d) (-5.1% 7d) (35.6% volume)
Earnings Calendar:
Market Cap: $ 56,267,270
https://www.cryo-cell.com/
Sec Filling | Patents | 94 employees

(US) Cryo-Cell International Inc., founded in 1989, is the world’s first private cord blood bank and is internationally recognized as the industry leader. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. Cryo-Cell’s mission is to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, and support the advancement of regenerative medicine. Cryo-Cell aims to help more patients significantly improve their lives through the utilization of the unique immunomodulatory and potential regenerative properties found in the cord blood and cord tissue. In February 2021, Cryo-Cell entered into an exclusive, collaborative license agreement with Duke University that grants Cryo-Cell the rights to certain intellectual property, proprietary processes and regulatory/clinical data related to cord blood and cord tissue developed at The Marcus Center for Cellular Cures at Duke University. Cryo-Cell anticipates opening infusion clinics to treat patients with conditions such as autism, cerebral palsy, and traumatic brain injuries under the rights granted to Duke University through the FDA’s Expanded Access Program. In addition to these, the license agreement includes other clinical indications currently being studied, such as adult stroke, multiple sclerosis, osteoarthritis and COVID-19.

t-cell covid

add to watch list Paper trade email alert is off

Aeva Technologies Inc

AEVA 4 | $3.29 -4.36% 130K

Manufacturing

(0.0% 1d) (-31.9% 1m) (218.5% 1y) (0.0% 2d) (0.0% 3d) (-11.8% 7d) (22.03% volume)
Earnings Calendar:
Market Cap: $ 173,613,300
https://www.aeva.ai
Sec Filling | Patents | 2021 employees

(US) Founded in 2017 by former Apple engineers Soroush Salehian and Mina Rezk, and led by a multidisciplinary team of engineers and operators, Aeva is building the next-generation of sensing and perception for autonomous vehicles and beyond. Aeva is backed by Adage Capital, Porsche SE, Lux Capital and Canaan Partners, amongst others

vehicles

add to watch list Paper trade email alert is off

Aterian Inc

ATER | $2.33 4.96% 45K

Manufacturing

(0.0% 1d) (495.7% 1m) (162.3% 1y) (0.0% 2d) (0.0% 3d) (-14.0% 7d) (-26.97% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 214,508,200
https://www.aterian.io
Sec Filling | Patents | n/a employees

Aterian, Inc. is a leading technology-enabled consumer products platform that builds, acquires, and partners with best-in-class e-commerce brands by harnessing proprietary software and an agile supply chain to create top selling consumer products. The Company’s cloud-based platform, Artificial Intelligence Marketplace Ecommerce Engine (AIMEE™), leverages machine learning, natural language processing and data analytics to streamline the management of products at scale across the world’s largest online marketplaces, including Amazon, Shopify and Walmart. Aterian has thousands of SKUs across 14 owned and operated brands and sells products in multiple categories, including home and kitchen appliances, health and wellness, beauty and consumer electronics.

brands artificial intelligence electronics machine learning

add to watch list Paper trade email alert is off

ComSovereign Holding Corp

COMS | $0.24 2.5K

Manufacturing

(0.0% 1d) (19.9% 1m) (-89.0% 1y) (0.0% 2d) (0.0% 3d) (18.4% 7d) (11.44% volume)
Earnings Calendar:
Market Cap: $ 646,857
https://www.comsovereign.com/
Sec Filling | Patents | 112 employees

(US) COMSovereign Holding Corp. (Nasdaq: COMS) has assembled a portfolio of communications technology companies that enhance connectivity across the entire data transmission spectrum. Through strategic acquisitions and organic research and development efforts, COMSovereign has become a U.S.-based communications provider able to provide 4G LTE Advanced and 5G-NR telecom solutions to network operators and enterprises.

acquisitions communication 5g

add to watch list Paper trade email alert is off

PetVivo Holdings Inc

PETV | $0.615 12K

Manufacturing

(0.0% 1d) (-38.5% 1m) (-77.6% 1y) (0.0% 2d) (0.0% 3d) (14.5% 7d) (-74.56% volume)
Earnings Calendar: 2022-06-09
Market Cap: $ 10,313,561
https://petvivo.com
Sec Filling | Patents | 2 employees

PetVivo Holdings, Inc. is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

treatment injection animals

add to watch list Paper trade email alert is off